{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:58:05Z","timestamp":1791082685415,"version":"4.1.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Avidity Biosciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular disease in which genetic mutations activate DUX4 expression in skeletal muscle. Currently, there are no approved therapies for FSHD. We developed Delpacibart braxlosiran (del-brax, also known as AOC 1020), an antibody oligonucleotide conjugate (AOC), for the treatment of FSHD that is designed to specifically target and reduce DUX4 mRNA in skeletal muscle. AOC 1020 is composed of DUX4 mRNA-targeting small interfering RNA (siRNA), siDUX4.6, conjugated to a human transferrin receptor 1 (TfR1)-targeting monoclonal antibody to facilitate productive siRNA delivery to muscle. We demonstrate that siDUX4.6 reduces DUX4-regulated gene expression in FSHD patient-derived myotubes in vitro and in skeletal muscle of the ACTA1-MCM; FLExDUX4 FSHD mouse model in vivo. Single systemic intravenous treatment was sufficient to prevent DUX4-induced muscle weakness and fibrosis in this FSHD mouse model and reduce DUX4-regulated genes by \u223c75% 8 weeks post-dose. The pharmacokinetic profiles of AOCs with siDUX4.6 were comparable in murine and non-human primate muscle. These data demonstrate the potential of AOC 1020 to treat the underlying cause of FSHD by suppressing DUX4 expression in muscles of patients with FSHD. The safety and efficacy of AOC 1020 is currently being investigated in clinical trials.<\/jats:p>","DOI":"10.1093\/nar\/gkag301","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:37:49Z","timestamp":1774096669000},"source":"Crossref","is-referenced-by-count":4,"title":["Development of a\n                    <i>DUX4<\/i>\n                    -targeting antibody oligonucleotide conjugate as a therapy for FSHD"],"prefix":"10.1093","volume":"54","author":[{"given":"Barbora","family":"Malecova","sequence":"first","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sala","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garineh M","family":"Melikian","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Johns","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulin","family":"Erdogan","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Jordan","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Danny","family":"Arias","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingying","family":"Meng","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Dansereau","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel W","family":"Beppler","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata R","family":"Doppalapudi","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhua","family":"Huang","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Michael","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A","family":"Levin","sequence":"additional","affiliation":[{"name":"Avidity Biosciences, Inc. , 3020 Callan Rd, San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2026042721111245100_B1","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"2026042721111245100_B2","volume-title":"Population Estimates","author":"USCensusBureau","year":"2023"},{"key":"2026042721111245100_B3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.molmed.2020.09.008","article-title":"Therapeutic approaches in facioscapulohumeral muscular dystrophy","volume":"27","author":"Cohen","year":"2021","journal-title":"Trends Mol Med"},{"key":"2026042721111245100_B4","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1212\/WNL.0000000000006819","article-title":"Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy","volume":"92","author":"Goselink","year":"2019","journal-title":"Neurology"},{"key":"2026042721111245100_B5","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1002\/mus.880181315","article-title":"Facioscapulohumeral muscular dystrophy in the Dutch population","volume":"18","author":"Padberg","year":"1995","journal-title":"Muscle Nerve"},{"key":"2026042721111245100_B6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/mus.23949","article-title":"Risk of functional impairment in facioscapulohumeral muscular dystrophy","volume":"49","author":"Statland","year":"2014","journal-title":"Muscle Nerve"},{"key":"2026042721111245100_B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mus.20522","article-title":"Facioscapulohumeral muscular dystrophy","volume":"34","author":"Tawil","year":"2006","journal-title":"Muscle Nerve"},{"key":"2026042721111245100_B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2044-5040-4-12","article-title":"Facioscapulohumeral dystrophy: the path to consensus on pathophysiology","volume":"4","author":"Tawil","year":"2014","journal-title":"Skeletal Muscle"},{"key":"2026042721111245100_B9","doi-asserted-by":"publisher","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS One"},{"key":"2026042721111245100_B10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"2026042721111245100_B11","doi-asserted-by":"publisher","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet"},{"key":"2026042721111245100_B12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-genom-083118-014933","article-title":"The genetics and epigenetics of facioscapulohumeral muscular dystrophy","volume":"20","author":"Himeda","year":"2019","journal-title":"Annu Rev Genom Hum Genet"},{"key":"2026042721111245100_B13","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/cells10123322","article-title":"DUX4 role in normal physiology and in FSHD muscular dystrophy","volume":"10","author":"Mocciaro","year":"2021","journal-title":"Cells"},{"key":"2026042721111245100_B14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/ng.3858","article-title":"DUX-family transcription factors regulate zygotic genome activation in placental mammals","volume":"49","author":"De\u00a0Iaco","year":"2017","journal-title":"Nat Genet"},{"key":"2026042721111245100_B15","doi-asserted-by":"publisher","first-page":"e0160022","DOI":"10.1371\/journal.pone.0160022","article-title":"Influence of repressive histone and DNA methylation upon D4Z4 transcription in non-myogenic cells","volume":"11","author":"Das","year":"2016","journal-title":"PLoS One"},{"key":"2026042721111245100_B16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JND-200554","article-title":"Current therapeutic approaches in FSHD","volume":"8","author":"Wang","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"2026042721111245100_B18","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1093\/hmg\/ddy162","article-title":"Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle","volume":"27","author":"Campbell","year":"2018","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B19","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B20","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/hmg\/ddy400","article-title":"Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development","volume":"28","author":"van\u00a0den\u00a0Heuvel","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B22","doi-asserted-by":"publisher","first-page":"e1008754","DOI":"10.1371\/journal.pgen.1008754","article-title":"Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei","volume":"16","author":"Jiang","year":"2020","journal-title":"PLoS Genet"},{"key":"2026042721111245100_B23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMcibr1613559","article-title":"Targeting therapeutic oligonucleotides","volume":"376","author":"Levin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042721111245100_B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042721111245100_B26","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026042721111245100_B27","article-title":"Topline results from FORTITUDETM, a randomized phase 1\/2 trial evaluating AOC 1020 (del-brax) in adults with FSHD","volume-title":"32nd Annual FSHD Society International Research Conference on FSHD.","author":"Statland","year":"2025"},{"key":"2026042721111245100_B28","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1038\/s41467-018-06526-1","article-title":"6mer seed toxicity in tumor suppressive microRNAs","volume":"9","author":"Gao","year":"2018","journal-title":"Nat Commun"},{"key":"2026042721111245100_B29","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","article-title":"Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-siRNA conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J Med Chem"},{"key":"2026042721111245100_B30","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1093\/hmg\/ddt314","article-title":"Wnt\/beta-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells","volume":"22","author":"Block","year":"2013","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/ng.3846","article-title":"Conservation and innovation in the DUX4-family gene network","volume":"49","author":"Whiddon","year":"2017","journal-title":"Nat Genet"},{"key":"2026042721111245100_B32","first-page":"4419","article-title":"Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"2026042721111245100_B34","doi-asserted-by":"crossref","first-page":"bax020","DOI":"10.1093\/database\/bax020","article-title":"Ensembl core software resources: storage and programmatic access for DNA sequence and genome annotation","volume":"2017","author":"Ruffier","year":"2017","journal-title":"Database (Oxford)"},{"key":"2026042721111245100_B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2026042721111245100_B36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026042721111245100_B37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026042721111245100_B38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2026042721111245100_B39","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"NationalResearchCouncil","year":"2011","edition":"8 ed."},{"key":"2026042721111245100_B40","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1093\/nar\/gni178","article-title":"Real-time quantification of microRNAs by stem-loop RT-PCR","volume":"33","author":"Chen","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"2026042721111245100_B41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skeletal Muscle"},{"key":"2026042721111245100_B42","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/hmg\/ddg327","article-title":"Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation","volume":"12","author":"Winokur","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B43","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/JCI89401","article-title":"Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity","volume":"127","author":"Teveroni","year":"2017","journal-title":"J Clin Invest"},{"key":"2026042721111245100_B44","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"2026042721111245100_B45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"2026042721111245100_B46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"2026042721111245100_B47","doi-asserted-by":"publisher","first-page":"btae011","DOI":"10.1093\/bioinformatics\/btae011","article-title":"SeedMatchR: identify off-target effects mediated by siRNA seed regions in RNA-seq experiments","volume":"40","author":"Cazares","year":"2024","journal-title":"Bioinformatics"},{"key":"2026042721111245100_B48","doi-asserted-by":"publisher","first-page":"e0192657","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"key":"2026042721111245100_B49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tibs.2004.12.007","article-title":"siRNA and miRNA: an insight into RISCs","volume":"30","author":"Tang","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"2026042721111245100_B50","doi-asserted-by":"publisher","first-page":"8694","DOI":"10.1021\/jacs.6b04454","article-title":"Structural analysis of human Argonaute-2 bound to a modified siRNA guide","volume":"138","author":"Schirle","year":"2016","journal-title":"J Am Chem Soc"},{"key":"2026042721111245100_B51","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/jcm9092886","article-title":"Therapeutic strategies targeting DUX4 in FSHD","volume":"9","author":"Le\u00a0Gall","year":"2020","journal-title":"JCM"},{"key":"2026042721111245100_B52","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol Ther"},{"key":"2026042721111245100_B53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/ijms21030729","article-title":"DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy","volume":"21","author":"Lim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026042721111245100_B54","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3390\/biomedicines11092339","article-title":"A systemically administered unconjugated antisense oligonucleotide targeting DUX4 improves muscular injury and motor function in FSHD model mice","volume":"11","author":"Kakimoto","year":"2023","journal-title":"Biomedicines"},{"key":"2026042721111245100_B55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.omtn.2021.09.010","article-title":"Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy","volume":"26","author":"Bouwman","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026042721111245100_B56","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/hmg\/ddab136","article-title":"Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model","volume":"30","author":"Lu-Nguyen","year":"2021","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B57","doi-asserted-by":"publisher","first-page":"102791","DOI":"10.1016\/j.omtn.2025.102791","article-title":"DUX4 reduction and muscle function improvement by subcutaneous delivery of gapmer antisense oligonucleotides","volume":"37","author":"Zhang","year":"2026","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"2026042721111245100_B58","article-title":"Interim results from FORTITUDETM, a randomized phase 1\/2 trial evaluating AOC 1020 in adults with FSHD","volume-title":"31st Annual International Research Congress on FSHD","author":"Statland","year":"2024"},{"key":"2026042721111245100_B59","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/BF02509499","article-title":"Analysis of the organisation and localisation of the FSHD-associated tandem array in primates: implications for the origin and evolution of the 3.3 kb repeat family","volume":"105","author":"Clark","year":"1996","journal-title":"Chromosoma"},{"key":"2026042721111245100_B60","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2148-10-364","article-title":"A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene","volume":"10","author":"Leidenroth","year":"2010","journal-title":"BMC Evol Biol"},{"key":"2026042721111245100_B61","first-page":"4577","article-title":"Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4","volume":"25","author":"Eidahl","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B62","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat Genet"},{"key":"2026042721111245100_B63","doi-asserted-by":"publisher","first-page":"107823","DOI":"10.1016\/j.isci.2023.107823","article-title":"Antagonism among DUX family members evolved from an ancestral toxic single homeodomain protein","volume":"26","author":"Bosnakovski","year":"2023","journal-title":"iScience"},{"key":"2026042721111245100_B64","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/hmg\/ddad186","article-title":"snRNA-seq analysis in multinucleated myogenic FSHD cells identifies heterogeneous FSHD transcriptome signatures associated with embryonic-like program activation and oxidative stress-induced apoptosis","volume":"33","author":"Zheng","year":"2024","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B65","doi-asserted-by":"publisher","first-page":"e13695","DOI":"10.15252\/emmm.202013695","article-title":"Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7","volume":"13","author":"Banerji","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2026042721111245100_B66","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41598-022-04817-8","article-title":"Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers","volume":"12","author":"van\u00a0den\u00a0Heuvel","year":"2022","journal-title":"Sci Rep"},{"key":"2026042721111245100_B67","doi-asserted-by":"publisher","first-page":"113011","DOI":"10.1016\/j.expneurol.2019.113011","article-title":"Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy","volume":"320","author":"Mueller","year":"2019","journal-title":"Exp Neurol"},{"key":"2026042721111245100_B68","doi-asserted-by":"crossref","first-page":"ddaf183","DOI":"10.1093\/hmg\/ddaf183","article-title":"Identification of KHDC1L, a DUX4-regulated protein, as a novel plasma biomarker in facioscapulohumeral muscular dystrophy","volume":"35","author":"Sutliff","year":"2025","journal-title":"Hum Mol Genet"},{"key":"2026042721111245100_B69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"2026042721111245100_B70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med"},{"key":"2026042721111245100_B71","first-page":"175","article-title":"Facioscapulohumeral muscular dystrophy. A quantitative electromyographic study","volume":"47","author":"Stubgen","year":"2007","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"2026042721111245100_B72","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/mus.20613","article-title":"Sensitivity of motor unit potential analysis in facioscapulohumeral muscular dystrophy","volume":"34","author":"Podnar","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/7\/gkag301\/68171979\/gkag301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/54\/7\/gkag301\/68171979\/gkag301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:11:21Z","timestamp":1777338681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkag301\/8657739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkag301","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,24]]},"published":{"date-parts":[[2026,4,13]]},"article-number":"gkag301"}}